Voyageur Pharmaceuticals Ltd. (VYYRF)

Voyageur Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is December - November.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Aug 31, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020	Nov 30, 2019
Selling, General & Admin	0.94	0.99	1.45	1.23	0.71	0.53
Operating Expenses	1.34	1.22	1.61	1.97	1.14	0.53
Operating Income	-1.34	-1.22	-1.61	-1.97	-1.14	-0.53
Other Non Operating Income (Expenses)	-0.15	-0.13	-0.15	-0.08	-0	-0.02
EBT Excluding Unusual Items	-1.48	-1.35	-1.75	-2.05	-1.14	-0.55
Gain (Loss) on Sale of Assets	-	-	-0.01	-	-	-
Asset Writedown	-0.05	-0.05	-	-	-	-
Other Unusual Items	-	-	0	-	-	-
Pretax Income	-1.53	-1.4	-1.75	-2.05	-1.14	-0.55
Net Income	-1.53	-1.4	-1.75	-2.05	-1.14	-0.55
Net Income to Common	-1.53	-1.4	-1.75	-2.05	-1.14	-0.55
Shares Outstanding (Basic)	136	131	108	95	71	58
Shares Outstanding (Diluted)	136	131	108	95	71	58
Shares Change (YoY)	8.55%	21.03%	13.89%	34.24%	22.58%	21.07%
EPS (Basic)	-0.01	-0.01	-0.02	-0.02	-0.02	-0.01
EPS (Diluted)	-0.01	-0.01	-0.02	-0.02	-0.02	-0.01
Free Cash Flow	-0.5	-1.17	-2	-2.09	-0.43	-0.81
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.02	-0.01	-0.01
EBITDA	-1.34	-1.22	-1.6	-1.97	-0.98	-0.53
D&A For EBITDA	0	0	0.01	0.01	0.15	0
EBIT	-1.34	-1.22	-1.61	-1.97	-1.14	-0.53

Source: S&P Capital IQ. Standard template. Financial Sources.